Is NCT07647328 recruiting in Reno, NV?

Yes, NCT07647328 is currently recruiting participants at its Reno, NV location. This er-positive her2-negative breast cancer clinical trial is actively enrolling qualified participants.

Is participation in this Reno clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

ER-Positive HER2-Negative Breast Cancer Clinical Trial in Reno, NV

Q: How do I join the er-positive her2-negative breast cancer clinical trial in Reno?

To join this clinical trial in Reno, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This ER-Positive HER2-Negative Breast Cancer Study in Reno

The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Capable of giving signed informed consent.

Female or male, must be ≥ 18 years or as per locally allowed age limit for screening. Type of Participant and Disease Characteristics

Histologically or cytologically documented diagnosis of ER+, HER2- BC based on local laboratory results and who are not amenable to resection or radiation therapy with curative intent.

Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or metastatic ER+ disease.

De novo Stage 4 disease, or recurrence from early CD stage breast cancer after having received standard adjuvant endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week washout period is required after the last dose of tamoxifen prior to randomisation.

ECOG performance status of 0 or 1.

Adequate organ and marrow function. Sex and Contraceptive/Barrier Requirements

For those female or male patients who are not abstinent (in line with their preferred and usual lifestyle choice), and intend to be heterosexually active with a partner: Female patients must be using highly effective contraceptive measures from the time of screening until 4 weeks after discontinuation of study treatment, and must have a negative serum pregnancy test before first dose of any study treatment if they are of childbearing potential; or must have evidence of nonchild-bearing potential by fulfilling one of the following criteria at screening: (a) Post-menopausal, defined as women with cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause: (i) Age ≥ 60 years (ii) Age \< 60 years with serum estradiol and FSH level within the laboratory's reference range for post-menopausal females (iii) Previous bilateral surgical oophorectomy (iv) Medically confirmed ovarian failure OR (b) Pre/peri-menopausal, ie, not meeting the criteria for being post-menopausal. (i) Pre-/peri-menopausal women can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin \[also known as leuprolide\]). Patients must have concomitant treatment with LHRH agonists (goserelin or leuprorelin \[leuprolide\]) before or on the same day as the first dose of study treatment - and must be willing to continue on it for the duration of the study. Non sterilised male partners of a patient who is a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period. Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception from the time of screening throughout the total duration of the programme and the drug washout period to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Male patients can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin \[also known as leuprolide\]) unless the patients have clear orchiectomy medical history. Willingness to use 2 non-hormonal based methods of contraception throughout the study.

Exclusion Criteria

Participants who are not clinically indicated for endocrine therapy in combination with the CDK4/6 inhibitor ribociclib.

No evidence of advanced inoperable disease, or bone only disease with sclerotic/osteoblastic bone lesions only per standard of care imaging.

Have advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term, and/or pulmonary lymphangitis.

Persistent treatment-induced non-haematological toxicities (CTCAE Grade \> 2).

Known active infection including tuberculosis HBV and HCV.

Known to have tested positive for HIV. Participants with HIV may be enrolled if they fulfil the criteria recommended by FDA and ASCO guidelines.

Any clinically important abnormalities in heart conduction patterns; participants with pacemakers or medically controlled atrial fibrillation are not excluded.

Ongoing symptomatic hypotension.

Pregnant or lactating women or patients not willing to use highly effective contraception as defined in the protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Reno?

Yes, this clinical trial (NCT07647328) has an active research site in Reno, NV that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

ER-Positive HER2-Negative Breast Cancer Treatment Options in Reno, NV

If you're searching for er-positive her2-negative breast cancer treatment options in Reno, NV, this clinical trial (NCT07647328) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Reno research site is actively enrolling participants for this clinical trial. You'll receive care from experienced er-positive her2-negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all er-positive her2-negative breast cancer clinical trials near you to find additional studies recruiting in your area.

ER-Positive HER2-Negative Breast Cancer Clinical Trial in Reno, NV

Expert Care in Reno

IRB Approved

No-Cost Care

Apply for This Reno Location

Why Participate?

Simple Process